Skip to main content
Top
Published in: Clinical and Translational Oncology 1/2013

01-01-2013 | Research Article

Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience

Authors: Guo-Chun Zhang, Ning Liao, Zi-Bai Guo, Xue-Ke Qian, Chong-Yang Ren, Meng Yao, Xue-Rui Li, Kun Wang, Jian Zu

Published in: Clinical and Translational Oncology | Issue 1/2013

Login to get access

Abstract

Introduction

The timing of sentinel lymph node biopsy (SLNB) of breast cancer in the neoadjuvant setting is still controversial. We retrospectively analyzed a Chinese patient cohort with neoadjuvant chemotherapy (NAC) to evaluate the accuracy and axilla sparing potentials of different SLNB timings with methylene blue alone for lymphatic mapping.

Materials and methods

Patients with NAC and axillary lymph node dissection (ALND) and either pre- or post-NAC SLNB were eligible. Clinicopathological characteristics, identification rate (IR), false-negative rate (FNR), accuracy, and positive-predictive value were calculated and compared between the pre- and post-NAC SLNB group using appropriate statistical methods. Axilla sparing potentials of different SLNB timings were evaluated and compared.

Results

One hundred and fifteen eligible cases were included, and 58 had pre-NAC SLNB while the other 57 had post-NAC SLNB. Both groups were comparable in clinicopathological characteristics, neoadjuvant treatments and pathologic complete response rate. IR, FNR, and accuracy of SLNB, as pre-NAC versus post-NAC, were 100 versus 98.2 % (P = 0.496), 0 versus 8.0 % (P = 0.181), and 100 versus 96.4 % (P = 0.239), respectively. Post-NAC SLNB had significantly higher positive-predictive value for ALNs than pre-NAC SLNB (70.0 vs. 36.4 %, P = 0.014), suggesting as high as 63.6 % of ALND performed in the pre-NAC group could have been avoided while only 30 % of ALND in the post-NAC group were theoretically unnecessary.

Conclusions

Both SLNB timings of breast cancer patients with NAC were feasible and accurate. Although pre-NAC SLNB tends to be better in accuracy, post-NAC SLNB is significantly superior in terms of axilla sparing.
Literature
1.
go back to reference Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–398PubMedCrossRef Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–398PubMedCrossRef
2.
go back to reference Krag DN, Weaver DL, Alex JC et al (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2:335–339PubMedCrossRef Krag DN, Weaver DL, Alex JC et al (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2:335–339PubMedCrossRef
3.
go back to reference Goyal A, Mansel RE (2008) Recent advances in sentinel lymph node biopsy for breast cancer. Curr Opin Oncol 20:621–626PubMedCrossRef Goyal A, Mansel RE (2008) Recent advances in sentinel lymph node biopsy for breast cancer. Curr Opin Oncol 20:621–626PubMedCrossRef
4.
go back to reference Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRef Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRef
5.
go back to reference Liu SV, Melstrom L, Yao K et al (2011) Neoadjuvant therapy for breast cancer. J Surg Oncol 101:283–291CrossRef Liu SV, Melstrom L, Yao K et al (2011) Neoadjuvant therapy for breast cancer. J Surg Oncol 101:283–291CrossRef
6.
go back to reference Kuerer HM, Sahin AA, Hunt KK et al (1999) Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230:72–78PubMedCrossRef Kuerer HM, Sahin AA, Hunt KK et al (1999) Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230:72–78PubMedCrossRef
7.
go back to reference Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef
8.
go back to reference Veronesi P, Rodriguez-Fernandez J, Intra M (2007) Controversies in the use of sentinel nodes: microinvasion, post surgery and after preoperative systemic treatment. Breast 16(Suppl 2):S67–S70PubMedCrossRef Veronesi P, Rodriguez-Fernandez J, Intra M (2007) Controversies in the use of sentinel nodes: microinvasion, post surgery and after preoperative systemic treatment. Breast 16(Suppl 2):S67–S70PubMedCrossRef
9.
go back to reference Vigario A, Sapienza MT, Sampaio AP et al (2003) Primary chemotherapy effect in sentinel node detection in breast cancer. Clin Nucl Med 28:553–557PubMedCrossRef Vigario A, Sapienza MT, Sampaio AP et al (2003) Primary chemotherapy effect in sentinel node detection in breast cancer. Clin Nucl Med 28:553–557PubMedCrossRef
10.
go back to reference Pecha V, Kolarik D, Kozevnikova R et al (2011) Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer. doi: 10.1002/cncr.26102 Pecha V, Kolarik D, Kozevnikova R et al (2011) Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer. doi: 10.​1002/​cncr.​26102
11.
go back to reference Schrenk P, Hochreiner G, Fridrik M et al (2003) Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J 9:282–287PubMedCrossRef Schrenk P, Hochreiner G, Fridrik M et al (2003) Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J 9:282–287PubMedCrossRef
12.
go back to reference Papa MZ, Zippel D, Kaufman B et al (2008) Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 98:403–406PubMedCrossRef Papa MZ, Zippel D, Kaufman B et al (2008) Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 98:403–406PubMedCrossRef
13.
go back to reference Brown AS, Hunt KK, Shen J et al (2010) Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116:2878–2883PubMedCrossRef Brown AS, Hunt KK, Shen J et al (2010) Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116:2878–2883PubMedCrossRef
14.
go back to reference Cohen LF, Breslin TM, Kuerer HM et al (2000) Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 24:1266–1272PubMedCrossRef Cohen LF, Breslin TM, Kuerer HM et al (2000) Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 24:1266–1272PubMedCrossRef
15.
go back to reference Kilbride KE, Lee MC, Nees AV et al (2008) Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol 15:3252–3258PubMedCrossRef Kilbride KE, Lee MC, Nees AV et al (2008) Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol 15:3252–3258PubMedCrossRef
16.
go back to reference Menard JP, Extra JM, Jacquemier J et al (2009) Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy. Eur J Surg Oncol 35:916–920PubMedCrossRef Menard JP, Extra JM, Jacquemier J et al (2009) Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy. Eur J Surg Oncol 35:916–920PubMedCrossRef
17.
go back to reference Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23:2694–2702PubMedCrossRef Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23:2694–2702PubMedCrossRef
18.
go back to reference Burstein HJ, Harris LN, Gelman R et al (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46–53PubMedCrossRef Burstein HJ, Harris LN, Gelman R et al (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46–53PubMedCrossRef
19.
go back to reference Chevallier B, Roche H, Olivier JP et al (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223–228PubMedCrossRef Chevallier B, Roche H, Olivier JP et al (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223–228PubMedCrossRef
20.
go back to reference Xing Y, Foy M, Cox DD et al (2006) Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93:539–546PubMedCrossRef Xing Y, Foy M, Cox DD et al (2006) Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93:539–546PubMedCrossRef
21.
go back to reference van Deurzen CH, Vriens BE, Tjan-Heijnen VC et al (2009) Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer 45:3124–3130PubMedCrossRef van Deurzen CH, Vriens BE, Tjan-Heijnen VC et al (2009) Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer 45:3124–3130PubMedCrossRef
22.
go back to reference Kelly AM, Dwamena B, Cronin P et al (2009) Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol 16:551–563PubMedCrossRef Kelly AM, Dwamena B, Cronin P et al (2009) Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol 16:551–563PubMedCrossRef
23.
go back to reference Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106:4–16PubMedCrossRef Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106:4–16PubMedCrossRef
24.
go back to reference Tausch C, Konstantiniuk P, Kugler F et al (2008) Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol 15:3378–3383PubMedCrossRef Tausch C, Konstantiniuk P, Kugler F et al (2008) Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol 15:3378–3383PubMedCrossRef
25.
go back to reference Varghese P, Mostafa A, Abdel-Rahman AT et al (2007) Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer. Eur J Surg Oncol 33:147–152PubMedCrossRef Varghese P, Mostafa A, Abdel-Rahman AT et al (2007) Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer. Eur J Surg Oncol 33:147–152PubMedCrossRef
26.
go back to reference Classe JM, Bordes V, Campion L et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 27:726–732PubMedCrossRef Classe JM, Bordes V, Campion L et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 27:726–732PubMedCrossRef
Metadata
Title
Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience
Authors
Guo-Chun Zhang
Ning Liao
Zi-Bai Guo
Xue-Ke Qian
Chong-Yang Ren
Meng Yao
Xue-Rui Li
Kun Wang
Jian Zu
Publication date
01-01-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 1/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0885-0

Other articles of this Issue 1/2013

Clinical and Translational Oncology 1/2013 Go to the issue

Acknowledgements to Referees

Acknowledgements to Referees 2012

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine